Symbols / ATNM
ATNM Chart
About
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 35.10M |
| Enterprise Value | -18.87M | Income | -34.60M | Sales | 90.00K |
| Book/sh | 0.44 | Cash/sh | 1.71 | Dividend Yield | — |
| Payout | 0.00% | Employees | 25 | IPO | — |
| P/E | — | Forward P/E | -1.42 | PEG | — |
| P/S | 389.95 | P/B | 2.55 | P/C | — |
| EV/EBITDA | 0.51 | EV/Sales | -209.65 | Quick Ratio | 7.81 |
| Current Ratio | 7.96 | Debt/Eq | 8.29 | LT Debt/Eq | — |
| EPS (ttm) | -1.11 | EPS next Y | -0.79 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -33.76% |
| ROE | -133.09% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -63.24% | Profit Margin | 0.00% | Shs Outstand | 31.20M |
| Shs Float | 30.86M | Short Float | 3.37% | Short Ratio | 7.94 |
| Short Interest | — | 52W High | 2.41 | 52W Low | 1.02 |
| Beta | -0.30 | Avg Volume | 142.32K | Volume | 129.42K |
| Target Price | $5.00 | Recom | None | Prev Close | $1.07 |
| Price | $1.12 | Change | 5.14% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.00
Mean price target
2. Current target
$1.13
Latest analyst target
3. DCF / Fair value
$-7.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.13
Low
$2.00
High
$9.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-05-12 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-28 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-11-19 | reit | Stephens & Co. | Overweight → Overweight | $5 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-08-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-08-06 | main | Maxim Group | Buy → Buy | $5 |
| 2024-07-26 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-05-14 | init | Stephens & Co. | — → Overweight | $25 |
| 2024-05-02 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-04-30 | reit | Cantor Fitzgerald | Overweight → Overweight | $21 |
| 2024-04-29 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
- Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposiu - PR Newswire Mon, 01 Dec 2025 08
- Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? - Yahoo Finance Mon, 22 Dec 2025 08
- Actinium Pharmaceuticals stock rises after promising breast cancer therapy data - Investing.com Fri, 12 Dec 2025 08
- The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - TMX Newsfile Mon, 17 Nov 2025 08
- Why Is Actinium Pharmaceuticals Stock Rising Today? - Stocktwits Fri, 12 Dec 2025 08
- Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance ue, 02 Sep 2025 07
- Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Confer - PR Newswire Mon, 27 Oct 2025 07
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 11
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Br - PR Newswire Fri, 12 Dec 2025 08
- Actinium Highlights ATNM 400 Progress at SNMMI Conference - Yahoo Finance Wed, 02 Jul 2025 07
- High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment - Nasdaq Fri, 15 Mar 2024 07
- Actinium Shares Surge on Promising Trial Data Breakthrough - AD HOC NEWS ue, 18 Nov 2025 08
- Actinium Pharmaceuticals Rising: Clinical Trials Spark Interest - StocksToTrade ue, 25 Mar 2025 07
- Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficac - PR Newswire hu, 31 Jul 2025 07
- Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year? - Yahoo Finance Fri, 05 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -41.31M | -51.13M | -33.41M | -24.44M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -38.24M | -48.82M | -33.02M | -24.77M |
| ReconciledDepreciation | 811.00K | 790.00K | 699.00K | 524.00K |
| EBITDA | -41.31M | -51.13M | -33.41M | -24.44M |
| EBIT | -42.12M | -51.92M | -34.10M | -24.96M |
| NetInterestIncome | 3.88M | 3.10M | 1.09M | 190.00K |
| InterestIncome | 3.88M | 3.10M | 1.09M | 190.00K |
| NormalizedIncome | -38.24M | -48.82M | -33.02M | -24.77M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -38.24M | -48.82M | -33.02M | -24.77M |
| TotalExpenses | 42.12M | 52.00M | 35.13M | 26.11M |
| TotalOperatingIncomeAsReported | -42.12M | -51.92M | -34.10M | -24.96M |
| DilutedAverageShares | 30.07M | 26.60M | 24.14M | 20.57M |
| BasicAverageShares | 30.07M | 26.60M | 24.14M | 20.57M |
| DilutedEPS | -1.27 | -1.83 | -1.37 | -1.20 |
| BasicEPS | -1.27 | -1.83 | -1.37 | -1.20 |
| DilutedNIAvailtoComStockholders | -38.24M | -48.82M | -33.02M | -24.77M |
| NetIncomeCommonStockholders | -38.24M | -48.82M | -33.02M | -24.77M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -38.24M | -48.82M | -33.02M | -24.77M |
| NetIncomeIncludingNoncontrollingInterests | -38.24M | -48.82M | -33.02M | -24.77M |
| NetIncomeContinuousOperations | -38.24M | -48.82M | -33.02M | -24.77M |
| PretaxIncome | -38.24M | -48.82M | -33.02M | -24.77M |
| NetNonOperatingInterestIncomeExpense | 3.88M | 3.10M | 1.09M | 190.00K |
| InterestIncomeNonOperating | 3.88M | 3.10M | 1.09M | 190.00K |
| OperatingIncome | -42.12M | -51.92M | -34.10M | -24.96M |
| OperatingExpense | 42.12M | 52.00M | 35.13M | 26.11M |
| ResearchAndDevelopment | 30.05M | 38.67M | 23.14M | 18.03M |
| SellingGeneralAndAdministration | 12.08M | 13.33M | 12.00M | 8.08M |
| GeneralAndAdministrativeExpense | 12.08M | 13.33M | 12.00M | 8.08M |
| OtherGandA | 12.08M | 13.33M | 12.00M | 8.08M |
| TotalRevenue | 0.00 | 81.00K | 1.03M | 1.14M |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 31.20M | 27.63M | 25.67M | 22.14M |
| ShareIssued | 31.20M | 27.63M | 25.67M | 22.14M |
| TotalDebt | 1.57M | 2.11M | 2.58M | 310.00K |
| TangibleBookValue | 32.76M | 36.38M | 66.48M | 73.55M |
| InvestedCapital | 32.76M | 36.38M | 66.48M | 73.55M |
| WorkingCapital | 66.36M | 69.77M | 100.31M | 72.91M |
| NetTangibleAssets | 32.76M | 36.38M | 66.48M | 73.55M |
| CapitalLeaseObligations | 1.57M | 2.11M | 2.58M | 310.00K |
| CommonStockEquity | 32.76M | 36.38M | 66.48M | 73.55M |
| TotalCapitalization | 32.76M | 36.38M | 66.48M | 73.55M |
| TotalEquityGrossMinorityInterest | 32.76M | 36.38M | 66.48M | 73.55M |
| StockholdersEquity | 32.76M | 36.38M | 66.48M | 73.55M |
| RetainedEarnings | -375.83M | -337.58M | -288.76M | -255.75M |
| AdditionalPaidInCapital | 408.55M | 373.93M | 355.22M | 329.27M |
| CapitalStock | 31.00K | 28.00K | 26.00K | 22.00K |
| CommonStock | 31.00K | 28.00K | 26.00K | 22.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 44.14M | 45.07M | 47.71M | 6.84M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 35.99M | 36.57M | 37.08M | 3.00K |
| NonCurrentDeferredLiabilities | 35.00M | 35.00M | 35.00M | 0.00 |
| NonCurrentDeferredRevenue | 35.00M | 35.00M | 35.00M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 993.00K | 1.57M | 2.08M | 3.00K |
| LongTermCapitalLeaseObligation | 993.00K | 1.57M | 2.08M | 3.00K |
| CurrentLiabilities | 8.15M | 8.49M | 10.63M | 6.84M |
| OtherCurrentLiabilities | 998.00K | |||
| CurrentDeferredLiabilities | 0.00 | 998.00K | ||
| CurrentDeferredRevenue | 0.00 | 998.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 580.00K | 541.00K | 498.00K | 307.00K |
| CurrentCapitalLeaseObligation | 580.00K | 541.00K | 498.00K | 307.00K |
| PayablesAndAccruedExpenses | 7.57M | 7.95M | 10.13M | 5.54M |
| TotalAssets | 76.90M | 81.44M | 114.19M | 80.39M |
| TotalNonCurrentAssets | 2.39M | 3.18M | 3.25M | 639.00K |
| OtherNonCurrentAssets | 324.00K | 313.00K | 302.00K | |
| NonCurrentPrepaidAssets | 0.00 | |||
| NetPPE | 2.07M | 2.87M | 2.95M | 639.00K |
| AccumulatedDepreciation | -891.00K | -694.00K | -487.00K | -335.00K |
| GrossPPE | 2.96M | 3.56M | 3.44M | 974.00K |
| OtherProperties | 2.52M | 3.12M | 3.12M | 775.00K |
| MachineryFurnitureEquipment | 438.00K | 438.00K | 315.00K | 199.00K |
| CurrentAssets | 74.51M | 78.26M | 110.94M | 79.75M |
| OtherCurrentAssets | 357.00K | 226.00K | 65.00K | 61.00K |
| RestrictedCash | 0.00 | 396.00K | 392.00K | |
| PrepaidAssets | 1.25M | 1.36M | 1.57M | 1.47M |
| CashCashEquivalentsAndShortTermInvestments | 72.90M | 76.68M | 108.91M | 77.83M |
| CashAndCashEquivalents | 72.90M | 76.68M | 108.91M | 77.83M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -33.08M | -47.49M | 8.28M | -21.00M |
| RepaymentOfDebt | -9.00K | -4.00K | -49.00K | -85.00K |
| IssuanceOfCapitalStock | 29.25M | 14.61M | 23.16M | 35.30M |
| CapitalExpenditure | -11.00K | -153.00K | -366.00K | -133.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 73.23M | 76.99M | 109.61M | 78.22M |
| BeginningCashPosition | 76.99M | 109.61M | 78.22M | 64.00M |
| ChangesInCash | -3.76M | -32.62M | 31.39M | 14.22M |
| FinancingCashFlow | 29.32M | 14.87M | 23.11M | 35.22M |
| CashFlowFromContinuingFinancingActivities | 29.32M | 14.87M | 23.11M | 35.22M |
| ProceedsFromStockOptionExercised | 75.00K | 262.00K | 0.00 | 6.00K |
| NetCommonStockIssuance | 29.25M | 14.61M | 23.16M | 35.30M |
| CommonStockIssuance | 29.25M | 14.61M | 23.16M | 35.30M |
| NetIssuancePaymentsOfDebt | -9.00K | -4.00K | -49.00K | -85.00K |
| NetLongTermDebtIssuance | -9.00K | -4.00K | -49.00K | -85.00K |
| LongTermDebtPayments | -9.00K | -4.00K | -49.00K | -85.00K |
| InvestingCashFlow | -11.00K | -153.00K | -366.00K | -133.00K |
| CashFlowFromContinuingInvestingActivities | -11.00K | -153.00K | -366.00K | -133.00K |
| NetPPEPurchaseAndSale | -11.00K | -153.00K | -366.00K | -133.00K |
| PurchaseOfPPE | -11.00K | -153.00K | -366.00K | -133.00K |
| OperatingCashFlow | -33.07M | -47.34M | 8.64M | -20.87M |
| CashFlowFromContinuingOperatingActivities | -33.07M | -47.34M | 8.64M | -20.87M |
| ChangeInWorkingCapital | -932.00K | -3.15M | 38.17M | 1.69M |
| ChangeInOtherWorkingCapital | 34.00M | 998.00K | ||
| ChangeInOtherCurrentLiabilities | -530.00K | -494.00K | -272.00K | -342.00K |
| ChangeInOtherCurrentAssets | 0.00 | -527.00K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -387.00K | -2.18M | 4.59M | 1.20M |
| ChangeInPrepaidAssets | -15.00K | 49.00K | -158.00K | -161.00K |
| StockBasedCompensation | 5.29M | 3.84M | 2.79M | 1.69M |
| DepreciationAmortizationDepletion | 811.00K | 790.00K | 699.00K | 524.00K |
| DepreciationAndAmortization | 811.00K | 790.00K | 699.00K | 524.00K |
| Depreciation | 811.00K | 790.00K | ||
| NetIncomeFromContinuingOperations | -38.24M | -48.82M | -33.02M | -24.77M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ATNM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|